Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chemical Works of Gedeon RichterRGEDF +4.58%95 3-Year EBITDA Growth Rate is 17.70% as of Dec. 2025, which is 57% above its 10-year median of 11.30. GuruFocus rates RGEDF with a GF Score™ of 95/100 and a GF Value™ of $35.19 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 811 Drug Manufacturers companies, Chemical Works of Gedeon Richter ranks better than 65.1% on this metric.
During the past 12 months, Chemical Works of Gedeon Richter's average EBITDA Per Share Growth Rate was 3.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 19.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 19.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Chemical Works of Gedeon Richter was 46.40% per year. The lowest was -10.30% per year. And the median was 11.30% per year.
Chemical Works of Gedeon Richter (OTCPK:RGEDF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Chemical Works of Gedeon Richter 3-Year EBITDA Growth Rate Related Terms
RGEDF vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Chemical Works of Gedeon Richter's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemical Works of Gedeon Richter 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chemical Works of Gedeon Richter's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Chemical Works of Gedeon Richter's 3-Year EBITDA Growth Rate falls into.
Chemical Works of Gedeon Richter 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.70% mean?
Chemical Works of Gedeon Richter (RGEDF) has a 3-Year EBITDA Growth Rate of 17.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Chemical Works of Gedeon Richter and its competitors. This is 57% above median its historical median of 11.30. According to the industry distribution chart, Chemical Works of Gedeon Richter ranks #283 out of 811 companies in the Drug Manufacturers industry, placing it in the top 34.9%.
Is Chemical Works of Gedeon Richter's 3-Year EBITDA Growth Rate too high?
Chemical Works of Gedeon Richter's current 3-Year EBITDA Growth Rate of 17.70% is 57% above median its 10-year median of 11.30. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Chemical Works of Gedeon Richter's value of 17.70% is 101.1% above this industry median. Based on the distribution chart, Chemical Works of Gedeon Richter ranks #283 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chemical Works of Gedeon Richter has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemical Works of Gedeon Richter's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Chemical Works of Gedeon Richter ranks #283 out of 811 companies for 3-Year EBITDA Growth Rate. This puts Chemical Works of Gedeon Richter in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Chemical Works of Gedeon Richter's value of 17.70% is 101.1% above this benchmark. While the company's 10-year median is 11.30 vs. the industry median of 8.80, Chemical Works of Gedeon Richter has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemical Works of Gedeon Richter's current 3-Year EBITDA Growth Rate of 17.70% is 101.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Chemical Works of Gedeon Richter and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemical Works of Gedeon Richter's current 3-Year EBITDA Growth Rate is 17.70%, which is 57% above median its own 10-year median of 11.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemical Works of Gedeon Richter stock overvalued right now?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter (RGEDF) is currently considered Modestly Overvalued. The stock's GF Value™ is $35.19, compared to a current price of $39.76 — trading 13% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.70%, which is 57% above median its 10-year median of 11.30 and 101.1% above the Drug Manufacturers industry median of 8.80. Chemical Works of Gedeon Richter's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Chemical Works of Gedeon Richter (RGEDF), the current 3-Year EBITDA Growth Rate is 17.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemical Works of Gedeon Richter (RGEDF) Overvalued in 2026?
Based on GuruFocus' analysis, Chemical Works of Gedeon Richter stock appears to be overvalued.
The current stock price of $39.76 is trading 13% above its estimated GF Value™ of $35.19.
GuruFocus considers Chemical Works of Gedeon Richter to be Modestly Overvalued.
Key valuation signals for RGEDF:
3-Year EBITDA Growth Rate: 17.70% (57% above median its 10-year median of 11.30)
GF Value™: $35.19 vs. price of $39.76 (13% above fair value)
Industry Position: 101.1% above the Drug Manufacturers median (#283 of 811)
No single metric tells the full story. See the RGEDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women's Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
95GF Score
Get the complete analysis for RGEDF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEDF has been successfully added to your 
